Federico Aucejo, R Matthew Walsh, Koji Hashimoto, Hanna Hong, Chase J Wehrle, Keyue Sun, Chunbao Jiao, Andrea Schlegel, Charles Miller, David C H Kwon, Abby Gross, Erlind Allkushi, Melis Uysal, Maureen Whitsett Linganna, Noah X Tocci, Katheryn Stackhouse
Journal: Journal of surgical oncology 2025;131(5):879-887
PMID: 39155663
Primary liver malignancies are a serious and challenging global health concern. The most common primary tumors are hepatocellular carcinoma and cholangiocarcinoma. These diseases portend poor prognosis when presenting with progressive, extensive disease. There is a critical need for improved diagnosis, therapeutic intervention, and monitoring surveillance in liver-related malignancies. Liquid biopsy using ctDNA provides an opportunity for growth within these domains for liver-related malignancy. However, ctDNA is relatively understudied in this field compared with other solid tumor types, possibly due to the complex nature of the pathology. In this review, we aim to discuss ctDNA, the current literature, and future directions of this technology within primary liver malignancies.
© 2024 The Author(s). Journal of Surgical Oncology published by Wiley Periodicals LLC.
Full Text Sources:
Medical:
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.